Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by stanleyon Apr 18, 2013 5:19pm
168 Views
Post# 21278829

BRD Q1 EARNINGS, CC AND AGM May 14 2013

BRD Q1 EARNINGS, CC AND AGM May 14 2013

 

Brigus Gold to Release, Discuss Q1 Results May 14

2013-04-18 16:39 ET - News Release

 

Mr. Morgan Tyghe reports

BRIGUS GOLD ANNOUNCES Q1 EARNINGS RELEASE, CONFERENCE CALL AND AGM

Brigus Gold Corp. will conduct a teleconference in conjunction with its first-quarter earnings release on Tuesday, May 14, 2013. The teleconference will begin at noon Atlantic Time (11 a.m. Eastern Time) on the same day to discuss the first-quarter financial results.

Analysts and other interested parties wanting to participate in the call should dial 1-877-407-8133 (international 201-689-8040) at least 10 minutes prior to the start of the call. No passcode is required. The teleconference will be recorded. If you are unable to join the teleconference live, you can dial for playback toll-free at 1-877-660-6853 (international 201-612-7415); please use conference ID 412216. The event will be archived and available for replay until midnight on May 28, 2013. The teleconference will also be accompanied by a presentation made available on the company's website.

Brigus's annual general meeting will be held at the Delta Barrington Hotel in Halifax, N.S., on Wednesday, May 29, 2013, at 11 a.m. Atlantic Time (noon Eastern Time).

Bullboard Posts